Metabolic syndrome and ageing: Cognitive impairment and structural alterations of the central nervous system;Síndrome metabólico y envejecimiento: Déficit cognitivo y alteraciones estructurales del sistema nervioso central

Revista de Neurologia

Volumn 49, Issue 8, 2009, Pages 417-424

  Segura, B ^a   Jurado Luque, María Ángeles ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Aging; Cerebrovascular disease; Cognition; Dementia; Metabolic syndrome; Risk factors

Indexed keywords

HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

AGING; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; DEMENTIA; DISEASE ASSOCIATION; DYSLIPIDEMIA; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; REVIEW; RISK FACTOR; WHITE MATTER;

EID: 70350492287     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4908.2008425     Document Type: Review

References (99)

1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359 (Pubitemid 34251969)
2. Alegría E, Cordero A, Laclaustra M, Grima A, León M, Casanovas JA, et al. Prevalence of metabolic syndrome in the Spanish working population: MESYAS registry. Rev Esp Cardiol 2005; 58: 797-806. (Pubitemid 41131489)
3. Martínez-Larrad MT, Fernández-Pérez C, González-Sánchez JL, López A, Fernández- Álvarez J, Riviriego J, et al. Prevalence of the metabolic syndrome (ATP-III criteria). Population-based study of rural and urban areas in the Spanish province of Segovia. Med Clin (Barc) 2005; 125: 481-486
4. Alberti G. Introduction to the metabolic syndrome. Eur Heart J Suppl 2005; 7 (Suppl D): S3-5.
5. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005; 25: 391-406. (Pubitemid 41209007)
6. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Almeras N, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000; 102: 179-184 (Pubitemid 30451774)
7. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149: 1514-1520
8. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752
9. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, American Heart Association, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438
10. Kalmijn S, Foley D, White L, Burchfiel CM, Curb JD, Petrovitch H, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese- American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol 2000; 20: 2255-2260
11. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004; 292: 2237-2242 (Pubitemid 39473161)
12. Ho RC, Niti M, Yap KB, Kua EH, Ng TP. Metabolic syndrome and cognitive decline in Chinese older adults: results from the Singapore longitudinal ageing studies. Am J Geriatr Psychiatry 2008; 16: 519-522
13. Yaffe K, Haan M, Blackwell T, Cherkasova E, Whitmer RA, West N. Metabolic syndrome and cognitive decline in elderly Latinos: findings from the Sacramento Area Latino Study of Aging study. J Am Geriatr Soc 2007; 55: 758-762 (Pubitemid 46668964)
14. Komulainen P, Lakka TA, Kivipelto M, Hassinen M, Helkala EL, Haapala I, et al. Metabolic syndrome and cognitive function: a populationbased follow-up study in elderly women. Dement Geriatr Cogn Disord 2007; 23: 29-34. (Pubitemid 46005788)
15. Dik MG, Jonker C, Comijs HC, Deeg DJ, Kok A, Yaffe K, et al. Contribution of metabolic syndrome components to cognition in older individuals. Diabetes Care 2007; 30: 2655-2660 (Pubitemid 47547816)
16. Roriz-Cruz M, Rosset I, Wada T, Sakagami T, Ishine M, De Sá Roriz- Filho J, et al. Cognitive impairment and frontal-subcortical geriatric syndrome are associated with metabolic syndrome in a stroke-free population. Neurobiol Aging 2007; 28: 1723-1736 (Pubitemid 47384947)
17. Roriz-Cruz M, Rosset I, Wada T, Sakagami T, Ishine M, Roriz-Filho JS, et al. Stroke-independent association between metabolic syndrome and functional dependence, depression, and low quality of life in elderly community- dwelling Brazilian people. J Am Geriatr Soc 2007; 55: 374-382 (Pubitemid 46328104)
18. Razay G, Vreugdenhil A, Wilcock G. The metabolic syndrome and Alzheimer disease. Arch Neurol 2007; 64: 93-96
19. Vanhanen M, Koivisto K, Moilanen L, Helkala EL, Hanninen T, Soininen H, et al. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 2006; 67: 843-847 (Pubitemid 44394200)
20. Vilalta-Franch J, López-Pousa S, Garre-Olmo J, Turón-Estrada A, Pericot- Nierga I. Síndrome metabólico en la enfermedad de Alzheimer: influencias clínicas y evolutivas. Rev Neurol 2008; 46: 13-17 (Pubitemid 351162427)
21. Van den Berg E, Biessels GJ, De Craen AJ, Gussekloo J, Westendorp RG. The metabolic syndrome is associated with decelerated cognitive decline in the oldest old. Neurology 2007; 69: 979-985 (Pubitemid 47366051)
22. Vilalta-Franch J, López-Pousa S, Garre-Olmo J, Turón-Estrada A, Pericot- Nierga I. Mortalidad en pacientes con enfermedad de Alzheimer tratados con neurolépticos atípicos. Rev Neurol 2008; 46: 129-134 (Pubitemid 351767869)
23. Kurl S, Laukkanen JA, Niskanen L, Laaksonen D, Sivenius J, Nyyssonen K, et al. Metabolic syndrome and the risk of stroke in middle-aged men. Stroke 2006; 37: 806-811 (Pubitemid 43731913)
24. Boden-Albala B, Sacco RL, Lee HS, Grahame-Clarke C, Rundek T, Elkind MV, et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke 2008; 39: 30-35
25. Kwon HM, Kim BJ, Lee SH, Choi SH, Oh BH, Yoon BW. Metabolic syndrome as an independent risk factor of silent brain infarction in healthy people. Stroke 2006; 37: 466-470
26. Bokura H, Yamaguchi S, Iijima K, Nagai A, Oguro H. Metabolic syndrome is associated with silent ischemic brain lesions. Stroke 2008; 39: 1607-1609
27. Park JH, Kwon HM. Association between metabolic syndrome and previous ischemic lesions in patients with intracranial atherosclerotic stroke. Clin Neurol Neurosurg 2008; 110: 215-221
28. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005; 7: 424-430 (Pubitemid 41419409)
29. Bauer M, Lecrubier Y, Suppes T. Awareness of metabolic concerns in patients with bipolar disorder: a survey of European psychiatrists. Eur Psychiatry 2008; 23: 169-177
30. Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, Miller D, Haynes WG. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry 2008; 20: 131-137 (Pubitemid 352009283)
31. García-Portilla MP, Saiz PA, Benabarre A, Sierra P, Pérez J, Rodríguez A, et al. The prevalence of metabolic syndrome in patients with bipolar disorder. J Affect Disord 2008; 106: 197-201. (Pubitemid 350309669)
32. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19-32. (Pubitemid 41587460)
33. Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jarvelin MR, Lauren LH, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry 2005; 66: 559-563
34. De Hert MA, Van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006; 83: 87-93.
35. Heiskanen TH, Niskanen LK, Hintikka JJ, Koivumaa-Honkanen HT, Honkalampi KM, Haatainen KM, et al. Metabolic syndrome and depression: a cross-sectional analysis. J Clin Psychiatry 2006; 67: 1422-1427
36. Koponen H, Jokelainen J, Keinanen-Kiukaanniemi S, Kumpusalo E, Vanhala M. Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study. J Clin Psychiatry 2008; 69: 178-182
37. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005; 80: 45-53.
38. Bobes J, Arango C, Aranda P, Carmena R, García-García M, Rejas J, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 2007; 90: 162-173 (Pubitemid 46177553)
39. García-Portilla MP, Saiz PA, Bascarán MT, Martínez AS, Benabarre A, Sierra P, et al. Cardiovascular risk in patients with bipolar disorder. J Affect Disord 2009; 115: 302-308
40. Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, et al. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res 2005; 80: 9-18. (Pubitemid 41587459)
41. Taylor V, MacQueen G. Associations between bipolar disorder and metabolic syndrome: a review. J Clin Psychiatry 2006; 67: 1034-1041 (Pubitemid 44230873)
42. Rodríguez-Kú RJ. Síndrome metabólico y enfermedad vascular cerebral: evidencias en su tratamiento. Rev Neurol 2009; 48: 255-260
43. Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmacher T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003; 37: 193-220. (Pubitemid 36321747)
44. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007; 68 (Suppl 1): 20-27
45. Yumru M, Savas HA, Kurt E, Kaya MC, Selek S, Savas E, et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 2007; 98: 247-252 (Pubitemid 46151723)
46. De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 2008; 101: 295-303.
47. Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 2008; 101: 273-286
48. Mackin P, Bishop D, Watkinson H, Gallagher P, Ferrier IN. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry 2007; 191: 23-29 (Pubitemid 47035177)
49. Obisesan TO, Obisesan OA, Martins S, Alamgir L, Bond V, Maxwell C, et al. High blood pressure, hypertension, and high pulse pressure are associated with poorer cognitive function in persons aged 60 and older: the Third National Health and Nutrition Examination Survey. J Am Geriatr Soc 2008; 56: 501-509 (Pubitemid 351327944)
50. Reitz C, Tang MX, Manly J, Mayeux R, Luchsinger JA. Hypertension and the risk of mild cognitive impairment. Arch Neurol 2007; 64: 1734-1740 (Pubitemid 350254935)
51. Vicario A, Martínez CD, Baretto D, Díaz-Casale A, Nicolosi L. Hypertension and cognitive decline: impact on executive function. J Clin Hypertens (Greenwich) 2005; 7: 598-604.
52. Gupta R, Solanki RK, Pathak V. Blood pressure is associated with cognitive impairment in young hypertensives. World J Biol Psychiatry 2008; 9: 43-50. (Pubitemid 351250519)
53. Waldstein SR, Katzel LI. Interactive relations of central versus total obesity and blood pressure to cognitive function. Int J Obes (Lond) 2006; 30: 201-207
54. Suárez P, Castillo J, Pardellas H, Vadillo J, Lema M, Noya M. Comparación entre infartos lacunares hipertensivos y no hipertensivos. Rev Neurol 1998; 26: 807-810 (Pubitemid 29518546)
55. Sierra C, De La Sierra A, Salamero M, Sobrino J, Gómez-Angelats E, Coca A. Silent cerebral white matter lesions and cognitive function in middle-aged essential hypertensive patients. Am J Hypertens 2004; 17: 529-534 (Pubitemid 38726169)
56. Den Heijer T, Launer LJ, Prins ND, Van Dijk EJ, Vermeer SE, Hofman A, et al. Association between blood pressure, white matter lesions, and atrophy of the medial temporal lobe. Neurology 2005; 64: 263-267
57. Gianaros PJ, Greer PJ, Ryan CM, Jennings JR. Higher blood pressure predicts lower regional grey matter volume: consequences on short-term information processing. Neuroimage 2006; 31: 754-765
58. Salerno JA, Murphy DG, Horwitz B, DeCarli C, Haxby JV, Rapoport SI, et al. Brain atrophy in hypertension. A volumetric magnetic resonance imaging study. Hypertension 1992; 20: 340-348
59. Jeong SK, Nam HS, Son MH, Son EJ, Cho KH. Interactive effect of obesity indexes on cognition. Dement Geriatr Cogn Disord 2005; 19: 91-96
60. Gunstad J, Paul RH, Cohen RA, Tate DF, Spitznagel MB, Gordon E. Elevated body mass index is associated with executive dysfunction in otherwise healthy adults. Compr Psychiatry 2007; 48: 57-61. (Pubitemid 44826976)
61. Boeka AG, Lokken KL. Neuropsychological performance of a clinical sample of extremely obese individuals. Arch Clin Neuropsychol 2008; 23: 467-474
62. Razay G, Vreugdenhil A, Wilcock G. Obesity, abdominal obesity and Alzheimer disease. Dement Geriatr Cogn Disord 2006; 22: 173-176
63. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005; 62: 1556-1560 (Pubitemid 41434560)
64. Beydoun MA, Beydoun HA, Wang Y. Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. Obes Rev 2008; 9: 204-218 (Pubitemid 351550691)
65. Taki Y, Goto R, Evans A, Zijdenbos A, Neelin P, Lerch J, et al. Voxel-based morphometry of human brain with age and cerebrovascular risk factors. Neurobiol Aging 2004; 25: 455-463 (Pubitemid 38317343)
66. Ward MA, Carlsson CM, Trivedi MA, Sager MA, Johnson SC. The effect of body mass index on global brain volume in middle-aged adults: a cross sectional study. BMC Neurol 2005; 5: 23.
67. Pannacciulli N, Del Parigi A, Chen K, Le DS, Reiman EM, Tataranni PA. Brain abnormalities in human obesity: a voxel-based morphometric study. Neuroimage 2006; 31: 1419-1425 (Pubitemid 43949229)
68. Jagust W, Harvey D, Mungas D, Haan M. Central obesity and the aging brain. Arch Neurol 2005; 62: 1545-1548
69. Gazdzinski S, Kornak J, Weiner MW, Meyerhoff DJ. Body mass index and magnetic resonance markers of brain integrity in adults. Ann Neurol 2008; 63: 652-657
70. Helkala EL, Niskanen L, Viinamaki H, Partanen J, Uusitupa M. Short-term and long-term memory in elderly patients with NIDDM. Diabetes Care 1995; 18: 681-685
71. Kivipelto M, Helkala EL, Hanninen T, Laakso MP, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 2001; 56: 1683-1689 (Pubitemid 32574567)
72. Solomon A, Kareholt I, Ngandu T, Winblad B, Nissinen A, Tuomilehto J, et al. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology 2007; 68: 751-756 (Pubitemid 46667900)
73. Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis 2008; 196: 489-496 (Pubitemid 351146660)
74. Geroldi C, Frisoni GB, Paolisso G, Bandinelli S, Lamponi M, Abbatecola AM, et al. Insulin resistance in cognitive impairment: the InCHIANTI study. Arch Neurol 2005; 62: 1067-1072 (Pubitemid 41043726)
75. Mielke MM, Zandi PP, Sjogren M, Gustafson D, Ostling S, Steen B, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 2005; 64: 1689-1695 (Pubitemid 40695799)
76. Li G, Shofer JB, Kukull WA, Peskind ER, Tsuang DW, Breitner JC, et al. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology 2005; 65: 1045-1050 (Pubitemid 41429629)
77. Reitz C, Luchsinger J, Tang MX, Manly J, Mayeux R. Impact of plasma lipids and time on memory performance in healthy elderly without dementia. Neurology 2005; 64: 1378-1383 (Pubitemid 40570505)
78. Brands AM, Kessels RP, Hoogma RP, Henselmans JM, van der Beek Boter JW, Kappelle LJ, et al. Cognitive performance, psychological well-being, and brain magnetic resonance imaging in older patients with type 1 diabetes. Diabetes 2006; 55: 1800-1806 (Pubitemid 44324135)
79. Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004; 63: 658-663 (Pubitemid 39100821)
80. Ryan CM, Geckle MO. Circumscribed cognitive dysfunction in middle- aged adults with type 2 diabetes. Diabetes Care 2000; 23: 1486-1493
81. Jacobson AM, Musen G, Ryan CM, Silvers N, Cleary P, Waberski B, et al, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Longterm effect of diabetes and its treatment on cognitive function. N Engl J Med 2007; 356: 1842-1852
82. Van den Berg E, De Craen AJ, Biessels GJ, Gussekloo J, Westendorp RG. The impact of diabetes mellitus on cognitive decline in the oldest of the old: a prospective population-based study. Diabetologia 2006; 49: 2015-2023 (Pubitemid 44168467)
83. Sommerfield AJ, Deary IJ, Frier BM. Acute hyperglycemia alters mood state and impairs cognitive performance in people with type 2 diabetes. Diabetes Care 2004; 27: 2335-2340
84. Bruehl H, Rueger M, Dziobek I, Sweat V, Tirsi A, Javier E, et al. Hypothalamic- pituitary-adrenal axis dysregulation and memory impairments in type 2 diabetes. J Clin Endocrinol Metab 2007; 92: 2439-2445 (Pubitemid 47037340)
85. Abbatecola AM, Paolisso G, Lamponi M, Bandinelli S, Lauretani F, Launer L, et al. Insulin resistance and executive dysfunction in older persons. J Am Geriatr Soc 2004; 52: 1713-1718 (Pubitemid 41709926)
86. Knopman DS, Mosley TH, Catellier DJ, Sharrett AR, Atherosclerosis Risk in Communities (ARIC) Study. Cardiovascular risk factors and cerebral atrophy in a middle-aged cohort. Neurology 2005; 65: 876-881
87. Manschot SM, Brands AM, Van der Grond J, Kessels RP, Algra A, Kappelle LJ, et al. Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 2006; 55: 1106-1113 (Pubitemid 44100188)
88. Jongen C, Van der Grond J, Kappelle LJ, Biessels GJ, Viergever MA, Pluim JP, et al. Automated measurement of brain and white matter lesion volume in type 2 diabetes mellitus. Diabetologia 2007; 50: 1509-1516 (Pubitemid 46879017)
89. Van Harten B, Oosterman J, Muslimovic D, Van Loon BJ, Scheltens P, Weinstein HC. Cognitive impairment and MRI correlates in the elderly patients with type 2 diabetes mellitus. Age Ageing 2007; 36: 164-170 (Pubitemid 46455395)
90. Akisaki T, Sakurai T, Takata T, Umegaki H, Araki A, Mizuno S, et al. Cognitive dysfunction associates with white matter hyperintensities and subcortical atrophy on magnetic resonance imaging of the elderly diabetes mellitus Japanese elderly diabetes intervention trial (J-EDIT). Diabetes Metab Res Rev 2006; 22: 376-384 (Pubitemid 44446433)
91. Den Heijer T, Vermeer SE, Van Dijk EJ, Prins ND, Koudstaal PJ, Hofman A, et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 2003; 46: 1604-1610 (Pubitemid 38005322)
92. Musen G, Lyoo IK, Sparks CR, Weinger K, Hwang J, Ryan CM, et al. Effects of type 1 diabetes on gray matter density as measured by voxel- based morphometry. Diabetes 2006; 55: 326-333 (Pubitemid 43343260)
93. Gold SM, Dziobek I, Sweat V, Tirsi A, Rogers K, Bruehl H, et al. Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. Diabetologia 2007; 50: 711-719 (Pubitemid 46355836)
94. Kumar A, Haroon E, Darwin C, Pham D, Ajilore O, Rodríguez G, et al. Gray matter prefrontal changes in type 2 diabetes detected using MRI. J Magn Reson Imaging 2008; 27: 14-19
95. Brands AM, Biessels GJ, Kappelle LJ, De Haan EH, De Valk HW, Algra A, et al. Cognitive functioning and brain MRI in patients with type 1 and type 2 diabetes mellitus: a comparative study. Dement Geriatr Cogn Disord 2007; 23: 343-350 (Pubitemid 46631942)
96. Chabriat H, Pappata S, Poupon C, Clark CA, Vahedi K, Poupon F, et al. Clinical severity in CADASIL related to ultrastructural damage in white matter: in vivo study with diffusion tensor MRI. Stroke 1999; 30: 2637-2643
97. O'Sullivan M, Jones DK, Summers PE, Morris RG, Williams SC, Markus HS. Evidence for cortical 'disconnection' as a mechanism of agerelated cognitive decline. Neurology 2001; 57: 632-638
98. Nitkunan A, Barrick TR, Charlton RA, Clark CA, Markus HS. Multi-modal MRI in cerebral small vessel disease: its relationship with cognition and sensitivity to change over time. Stroke 2008; 39: 1999-2005.
99. Park K, Yasuda N, Toyonaga S, Yamada SM, Nakabayashi H, Nakasato M, et al. Significant association between leukoaraiosis and metabolic syndrome in healthy subjects. Neurology 2007; 69: 974-978 (Pubitemid 47366050)